Proinflammatory Cytokine Release Pathway

The Proinflammatory Cytokine Release Pathway is a complex biological signaling network responsible for initiating and sustaining the body's inflammatory response to pathogens, tissue damage, and other stressors [1, 4]. This pathway involves the coordinated production and secretion of signaling proteins known as proinflammatory cytokines, including Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6), primarily by innate immune cells like macrophages and dendritic cells [1, 7, 8]. Upon release, these cytokines bind to their respective receptors on target cells, activating downstream intracellular signaling cascades such as the NF-κB, MAPK, and JAK/STAT pathways, which lead to the further expression of inflammatory genes and the recruitment of additional immune cells [2, 7, 10]. While this process is vital for host defense and wound healing, its chronic or excessive activation is a hallmark of numerous pathologies, including rheumatoid arthritis, inflammatory bowel disease, and life-threatening cytokine release syndrome (CRS) [2, 4, 16]. Therapeutic strategies targeting this pathway include monoclonal antibodies that neutralize specific cytokines, receptor antagonists that block signaling, and small-molecule inhibitors that disrupt intracellular transduction, all aimed at restoring immune homeostasis [3, 5, 11, 17].

Other names

Cytokine release cascadePro-inflammatory signaling pathwayInflammatory cytokine pathwayCytokine storm pathway

Drugs targeting this pathway act by neutralizing circulating proinflammatory cytokines, competitively inhibiting cytokine receptors, or blocking intracellular signaling molecules such as Janus kinases (JAKs) and NF-κB to prevent the transcription and release of inflammatory mediators.